Trial Profile
Safety and Efficacy of AS-3201 in the Treatment of Diabetic Sensorimotor Polyneuropathy
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Apr 2022
Price :
$35
*
At a glance
- Drugs Ranirestat (Primary)
- Indications Diabetic neuropathies
- Focus Registrational; Therapeutic Use
- Sponsors Sumitomo Pharma
- 22 Feb 2012 Planned number of patients changed to 500.
- 01 Oct 2005 New trial record.